On January 6, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that Neil Klompas, Zymeworks’ Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 9:45 a.m. ET (Press release, Zymeworks, JAN 6, 2022, View Source [SID1234598378]). The presentation will be webcast live and available for replay on Zymeworks’ website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2022 Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to pursue well-validated but hard-to-drug targets, reported that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET (Press release, Jnana Therapeutics, JAN 6, 2022, View Source [SID1234598377]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2022 Be The Match BioTherapies and Atara Biotherapeutics, Inc. (Nasdaq: ATRA), reported an extension of their collaboration to provide high-quality healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for patients with cancer and autoimmune diseases (Press release, Atara Biotherapeutics, JAN 6, 2022, View Source [SID1234598376]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This multi-year partnership leverages the capabilities of Be The Match BioTherapies to source healthy donor cells from the Be The Match Registry with over 22 million genetically diverse human leukocyte antigen (HLA) immune profiles.

"Atara and Be The Match BioTherapies share an aspiration to serve every patient, and this partnership will allow us to deliver treatments to the patient populations that our organization was founded to help," said Chris McClain, Senior Vice President, Sales and Business Development at Be The Match BioTherapies. "We are proud to provide a consistent supply of high-quality, compliant, and consented HLA-specific starting material to support Atara’s tabelecleucel (tab-cel) program, including the ongoing Phase 3 ALLELE study, and its other pipeline candidates."

Since 2016, Be The Match BioTherapies has been a strategic supplier to Atara by providing the cellular starting material, peripheral blood mononuclear cells, from healthy donors with targeted HLA haplotypes for further manufacture and cryopreservation as inventory ready to be delivered to patients in need in just a few days. Cutting-edge bioinformatic insights into HLA genetics have supported Atara’s clinical programs by ensuring that for each product, an inventory of different manufactured lots is available for partial matching to patient HLA profiles to support efficacy and safety. Be The Match BioTherapies’ regulatory expertise ensures the collection of donor cells that meet FDA and varying international regulations, broadening the potential use of the therapies.

"With our recent EU regulatory marketing authorization application submission for tabelecleucel, the first-ever off-the-shelf allogeneic T-cell therapy to be reviewed by any regulatory agency in the world, we are one step closer to bringing this potentially transformative treatment to patients," said Matt Yedwabnick, Vice President, Global Supply Chain at Atara. "Our ability to deliver investigational medicines, including tab-cel, is reliant on sourcing high-quality healthy donor cells. Be The Match BioTherapies’ capabilities have been instrumental in identifying and supplying the starting materials to produce our multiple allogeneic T-cell and CAR-T immunotherapies in development."

On January 6, 2022 Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, reported that Ivan Dimov, Ph.D., Orca Bio’s chief executive officer and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference (Press release, Orca Bio, JAN 6, 2022, View Source [SID1234598375]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company presentation will take place virtually on Tuesday, January 11, 2022, at 6:30 AM PST (9:30 AM EST).

On January 6, 2022 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported an agreement with the Broad Institute to make available a whole exome target enrichment panel to enable next-generation sequencing (NGS) in canine genomics research (Press release, Twist Bioscience, JAN 6, 2022, View Source [SID1234598374]). The panel, known as the Twist Alliance Canine Exome Panel, is available for order today and will begin shipping in February 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Twist Alliance Canine Exome is the most current commercial exome-scale assay available for canine NGS research, and is based on updated content from CanFam v3.1. The panel was collaboratively designed with the Vertebrate Genomics Group at the Broad Institute by leveraging Twist’s rapid, iterative and flexible NGS platform to provide a rapid, off-the-shelf solution covering all coding exons of canine genes. In addition to exon-centric content, the assay includes regions of known importance in human cancers. When used with Twist’s robust end-to-end target enrichment workflows it enables cost-effective comparative studies between human and canine genomics to drive further insight into both human and canine health.

"In addition to the benefits to dogs from research using our canine exome panels, there may also be implications for human health, as both canines and humans suffer from similar inherited diseases, such as cancer, heart disease, rheumatoid arthritis and autoimmune disorders," said Emily M. Leproust, PhD, chief executive officer and co-founder of Twist Bioscience. "We are excited to expand our solutions in veterinary medicine, with the launch today of the Twist Alliance Canine Exome Panel."

About Twist Alliance Panels

In partnership with leading research institutions from around the world, Twist has curated a collection of high-quality target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole exome sequencing. The Twist Alliance Panels combine the strengths of precise, highly uniform oligonucleotide synthesis with the specialty expertise of leading scientific research partners.

Well designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing. This allows for more sensitive detection of target sequences and higher confidence variant detection.